Connection
J. Steven Leeder to Cytochrome P-450 Enzyme System
This is a "connection" page, showing publications J. Steven Leeder has written about Cytochrome P-450 Enzyme System.
|
|
Connection Strength |
|
|
|
|
|
6.696 |
|
|
|
-
Dinh JC, Pearce RE, Van Haandel L, Gaedigk A, Leeder JS. Characterization of Atomoxetine Biotransformation and Implications for Development of PBPK Models for Dose Individualization in Children. Drug Metab Dispos. 2016 07; 44(7):1070-9.
Score: 0.505
-
Leeder JS. Meaningful use and clinical utility of preemptive pharmacogenetic testing: (re)view from a CYP2D6 poor metabolizer. Clin Pharmacol Ther. 2015 Feb; 97(2):119-21.
Score: 0.461
-
Gaedigk A, Fuhr U, Johnson C, B?rard LA, Bradford D, Leeder JS. CYP2D7-2D6 hybrid tandems: identification of novel CYP2D6 duplication arrangements and implications for phenotype prediction. Pharmacogenomics. 2010 Jan; 11(1):43-53.
Score: 0.327
-
Pearce RE, Lu W, Wang Y, Uetrecht JP, Correia MA, Leeder JS. Pathways of carbamazepine bioactivation in vitro. III. The role of human cytochrome P450 enzymes in the formation of 2,3-dihydroxycarbamazepine. Drug Metab Dispos. 2008 Aug; 36(8):1637-49.
Score: 0.292
-
Gaedigk A, Baker DW, Totah RA, Gaedigk R, Pearce RE, Vyhlidal CA, Zeldin DC, Leeder JS. Variability of CYP2J2 expression in human fetal tissues. J Pharmacol Exp Ther. 2006 Nov; 319(2):523-32.
Score: 0.258
-
Gaedigk A, Leeder JS. Comments on Hoskins et al. [(2005) drug metab dispos 33:1564-1565]. Drug Metab Dispos. 2006 Mar; 34(3):504-5; author reply 506.
Score: 0.251
-
Gaedigk A, Gaedigk R, Leeder JS. CYP2D7 splice variants in human liver and brain: does CYP2D7 encode functional protein? Biochem Biophys Res Commun. 2005 Nov 04; 336(4):1241-50.
Score: 0.245
-
Pearce RE, Uetrecht JP, Leeder JS. Pathways of carbamazepine bioactivation in vitro: II. The role of human cytochrome P450 enzymes in the formation of 2-hydroxyiminostilbene. Drug Metab Dispos. 2005 Dec; 33(12):1819-26.
Score: 0.242
-
Parvez MM, Thakur A, Mehrotra A, Stancil S, Pearce RE, Basit A, Leeder JS, Prasad B. Age-Dependent Abundance of CYP450 Enzymes Involved in Metronidazole Metabolism: Application to Pediatric PBPK Modeling. Clin Pharmacol Ther. 2024 Oct; 116(4):1090-1099.
Score: 0.223
-
Kyler KE, Gaedigk A, Abdel-Rahman S, Staggs VS, Pearce RE, Toren P, Leeder JS, Shakhnovich V. Influence of novel CYP2C-haplotype on proton pump inhibitor pharmacokinetics in children. Clin Transl Sci. 2024 04; 17(4):e13782.
Score: 0.220
-
Zubiaur P, Leeder JS, Abad-Santos F, Gaedigk A. Response to "What is the Current Clinical Impact of the CYP2C:TG Haplotype?" Clin Pharmacol Ther. 2024 02; 115(2):184.
Score: 0.214
-
Zubiaur P, Soria-Chacartegui P, Boone EC, Prasad B, Dinh J, Wang WY, Zugbi S, Rodr?guez-Lopez A, Gonz?lez-Iglesias E, Leeder JS, Abad-Santos F, Gaedigk A. Impact of CYP2C:TG Haplotype on CYP2C19 Substrates Clearance In Vivo, Protein Content, and In Vitro Activity. Clin Pharmacol Ther. 2023 11; 114(5):1033-1042.
Score: 0.210
-
Rogan PK, Svojanovsky S, Leeder JS. Information theory-based analysis of CYP2C19, CYP2D6 and CYP3A5 splicing mutations. Pharmacogenetics. 2003 Apr; 13(4):207-18.
Score: 0.205
-
Lowry JA, Kearns GL, Abdel-Rahman SM, Nafziger AN, Khan IS, Kashuba AD, Schuetz EG, Bertino JS, van den Anker JN, Leeder JS. Cisapride: a potential model substrate to assess cytochrome P4503A4 activity in vivo. Clin Pharmacol Ther. 2003 Mar; 73(3):209-22.
Score: 0.204
-
Pearce RE, Vakkalagadda GR, Leeder JS. Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites. Drug Metab Dispos. 2002 Nov; 30(11):1170-9.
Score: 0.199
-
Seefelder C, Leeder JS. Cytochrome P450 pharmacogenetics and anaesthesia. Paediatr Anaesth. 2002 Nov; 12(9):810-1.
Score: 0.199
-
Pearce RE, Gotschall RR, Kearns GL, Leeder JS. Cytochrome P450 Involvement in the biotransformation of cisapride and racemic norcisapride in vitro: differential activity of individual human CYP3A isoforms. Drug Metab Dispos. 2001 Dec; 29(12):1548-54.
Score: 0.187
-
Leeder JS, Dinh JC, Gaedigk A, Staggs VS, Prasad B, Pearce RE. Ontogeny of Scaling Factors for Pediatric Physiology-Based Pharmacokinetic Modeling and Simulation: Microsomal Protein Per Gram of Liver. Drug Metab Dispos. 2022 01; 50(1):24-32.
Score: 0.185
-
Gaedigk A, Casley WL, Tyndale RF, Sellers EM, Jurima-Romet M, Leeder JS. Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations. Can J Physiol Pharmacol. 2001 Oct; 79(10):841-7.
Score: 0.185
-
Leeder JS, Lu X, Timsit Y, Gaedigk A. Non-monooxygenase cytochromes P450 as potential human autoantigens in anticonvulsant hypersensitivity reactions. Pharmacogenetics. 1998 Jun; 8(3):211-25.
Score: 0.147
-
Gaedigk A, Ingelman-Sundberg M, Miller NA, Leeder JS, Whirl-Carrillo M, Klein TE. The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature Database. Clin Pharmacol Ther. 2018 03; 103(3):399-401.
Score: 0.141
-
Wang LA, Gonzalez D, Leeder JS, Tyndale RF, Pearce RE, Benjamin DK, Kearns GL, Cohen-Wolkowiez M. Metronidazole Metabolism in Neonates and the Interplay Between Ontogeny and Genetic Variation. J Clin Pharmacol. 2017 02; 57(2):230-234.
Score: 0.130
-
Leeder JS, Gaedigk A, Lu X, Cook VA. Epitope mapping studies with human anti-cytochrome P450 3A antibodies. Mol Pharmacol. 1996 Feb; 49(2):234-43.
Score: 0.125
-
Rajasenan RS, Riley RJ, Leeder JS. Expression and inducibility of antigens in severe combined immunodeficient mice recognized by human anti-P450 antibodies. Toxicol Appl Pharmacol. 1995 Nov; 135(1):89-99.
Score: 0.123
-
Salem F, Johnson TN, Barter ZE, Leeder JS, Rostami-Hodjegan A. Age related changes in fractional elimination pathways for drugs: assessing the impact of variable ontogeny on metabolic drug-drug interactions. J Clin Pharmacol. 2013 Aug; 53(8):857-65.
Score: 0.104
-
Riley RJ, Smith G, Wolf CR, Cook VA, Leeder JS. Human anti-endoplasmic reticulum autoantibodies produced in aromatic anticonvulsant hypersensitivity reactions recognise rodent CYP3A proteins and a similarly regulated human P450 enzyme(s) Biochem Biophys Res Commun. 1993 Feb 26; 191(1):32-40.
Score: 0.102
-
Leeder JS, Riley RJ, Cook VA, Spielberg SP. Human anti-cytochrome P450 antibodies in aromatic anticonvulsant-induced hypersensitivity reactions. J Pharmacol Exp Ther. 1992 Oct; 263(1):360-7.
Score: 0.099
-
Yang X, Zhang B, Molony C, Chudin E, Hao K, Zhu J, Gaedigk A, Suver C, Zhong H, Leeder JS, Guengerich FP, Strom SC, Schuetz E, Rushmore TH, Ulrich RG, Slatter JG, Schadt EE, Kasarskis A, Lum PY. Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. Genome Res. 2010 Aug; 20(8):1020-36.
Score: 0.084
-
Leeder JS, Cannon M, Nakhooda A, Spielberg SP. Drug metabolite toxicity assessed in human lymphocytes with a purified, reconstituted cytochrome P-450 system. J Pharmacol Exp Ther. 1988 Jun; 245(3):956-62.
Score: 0.073
-
Blake MJ, Gaedigk A, Pearce RE, Bomgaars LR, Christensen ML, Stowe C, James LP, Wilson JT, Kearns GL, Leeder JS. Ontogeny of dextromethorphan O- and N-demethylation in the first year of life. Clin Pharmacol Ther. 2007 Apr; 81(4):510-6.
Score: 0.067
-
Blake MJ, Abdel-Rahman SM, Pearce RE, Leeder JS, Kearns GL. Effect of diet on the development of drug metabolism by cytochrome P-450 enzymes in healthy infants. Pediatr Res. 2006 Dec; 60(6):717-23.
Score: 0.066
-
Pearce RE, Leeder JS, Kearns GL. Biotransformation of fluticasone: in vitro characterization. Drug Metab Dispos. 2006 Jun; 34(6):1035-40.
Score: 0.063
-
Shelepova T, Nafziger AN, Victory J, Kashuba AD, Rowland E, Zhang Y, Sellers E, Kearns G, Leeder JS, Gaedigk A, Bertino JS. Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail. J Clin Pharmacol. 2005 Dec; 45(12):1413-21.
Score: 0.062
-
Leeder JS, Gaedigk R, Marcucci KA, Gaedigk A, Vyhlidal CA, Schindel BP, Pearce RE. Variability of CYP3A7 expression in human fetal liver. J Pharmacol Exp Ther. 2005 Aug; 314(2):626-35.
Score: 0.059
-
Chainuvati S, Nafziger AN, Leeder JS, Gaedigk A, Kearns GL, Sellers E, Zhang Y, Kashuba AD, Rowland E, Bertino JS. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail". Clin Pharmacol Ther. 2003 Nov; 74(5):437-47.
Score: 0.053
-
Leeder JS. Pharmacogenetics and pharmacogenomics. Pediatr Clin North Am. 2001 Jun; 48(3):765-81.
Score: 0.045
-
Streetman DS, Bleakley JF, Kim JS, Nafziger AN, Leeder JS, Gaedigk A, Gotschall R, Kearns GL, Bertino JS. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail". Clin Pharmacol Ther. 2000 Oct; 68(4):375-83.
Score: 0.043
-
de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet. 1999 Dec; 37(6):485-505.
Score: 0.041
-
Kashuba AD, Nafziger AN, Kearns GL, Leeder JS, Gotschall R, Gaedigk A, Bertino JS. Limitations of dextromethorphan N-demethylation as a measure of CYP3A activity. Pharmacogenetics. 1999 Aug; 9(4):453-62.
Score: 0.040
-
Henne KR, Gaedigk A, Gupta G, Leeder JS, Rettie AE. Chiral phase analysis of warfarin enantiomers in patient plasma in relation to CYP2C9 genotype. J Chromatogr B Biomed Sci Appl. 1998 Jun 12; 710(1-2):143-8.
Score: 0.037
-
Leeder JS. Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs. Epilepsia. 1998; 39 Suppl 7:S8-16.
Score: 0.036
-
Leeder JS, Kearns GL. Pharmacogenetics in pediatrics. Implications for practice. Pediatr Clin North Am. 1997 Feb; 44(1):55-77.
Score: 0.033
-
Riley RJ, Leeder JS. In vitro analysis of metabolic predisposition to drug hypersensitivity reactions. Clin Exp Immunol. 1995 Jan; 99(1):1-6.
Score: 0.029
-
Shaw K, Amstutz U, Hildebrand C, Rassekh SR, Hosking M, Neville K, Leeder JS, Hayden MR, Ross CJ, Carleton BC. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children. Pediatr Blood Cancer. 2014 Jun; 61(6):1055-62.
Score: 0.027
-
Ghodke-Puranik Y, Thorn CF, Lamba JK, Leeder JS, Song W, Birnbaum AK, Altman RB, Klein TE. Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2013 Apr; 23(4):236-41.
Score: 0.026
-
Kang P, Liao M, Wester MR, Leeder JS, Pearce RE, Correia MA. CYP3A4-Mediated carbamazepine (CBZ) metabolism: formation of a covalent CBZ-CYP3A4 adduct and alteration of the enzyme kinetic profile. Drug Metab Dispos. 2008 Mar; 36(3):490-9.
Score: 0.018
-
Blake MJ, Castro L, Leeder JS, Kearns GL. Ontogeny of drug metabolizing enzymes in the neonate. Semin Fetal Neonatal Med. 2005 Apr; 10(2):123-38.
Score: 0.015
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|